EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access

Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer

Alison M Schram, Koichi Goto, Dong-Wan Kim, Teresa Macarulla, Antoine Hollebecque, Eileen M O'Reilly, Sai-Hong Ignatius Ou, Jordi Rodon, Sun Young Rha, Kazumi Nishino, Michaël Duruisseaux, Joon Oh Park und 21 weitere

New England Journal of Medicine · 06.02.2025 · 392 (6) · 566-576

DOI: 10.1056/nejmoa2405008 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 06.02.2025. Verfasst von Alison M Schram und 32 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Neoplasms, Neuregulin-1, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 152-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Merus N.V..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalNeoplasmsNeuregulin-1Oncogene Proteins, FusionAntibodies, BispecificAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedProgression-Free SurvivalErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-3Protein MultimerizationSignal TransductionInfusions, IntravenousDrug Administration ScheduleDiarrheaFatigueNauseaInjection Site ReactionYoung AdultTreatment Outcome

Substanzen

Antineoplastic Agents, ImmunologicalNeuregulin-1Oncogene Proteins, FusionErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-3Antibodies, BispecificImmunoglobulin GERBB2 protein, humanERBB3 protein, humanNRG1 protein, human

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York.
  • National Cancer Center Hospital East, Kashiwa, Japan.
  • Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Vall d'Hebrón University Hospital, Vall d'Hebrón Institute of Oncology, Barcelona.
  • Gustave Roussy, Département d'Innovation Thérapeutique et Essais Précoces, Villejuif, France.
  • Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange.

ORCID-Profile: Emiliano Calvo

Förderung

  • NCI NIH HHS
  • Merus N.V.

Zitieren

APA

Schram, A. M., Goto, K., Kim, D. W., Macarulla, T., Hollebecque, A., O'Reilly, E. M., Ou, S. I., Rodon, J., Rha, S. Y., Nishino, K., Duruisseaux, M., Park, J. O., Neuzillet, C., Liu, S. V., Weinberg, B. A., Cleary, J. M., Calvo, E., Umemoto, K., Nagasaka, M., …, & eNRGy Investigators (2025). Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer. New England Journal of Medicine, 392(6), 566-576. https://doi.org/10.1056/nejmoa2405008

Vancouver

Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, et al. Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer. New England Journal of Medicine. 2025;392(6):566-576. doi:10.1056/nejmoa2405008

BibTeX
@article{Schram2025,
  author = {Schram, Alison M and Goto, Koichi and Kim, Dong-Wan and Macarulla, Teresa and Hollebecque, Antoine and O'Reilly, Eileen M and Ou, Sai-Hong Ignatius and Rodon, Jordi and Rha, Sun Young and Nishino, Kazumi and Duruisseaux, Michaël and Park, Joon Oh and Neuzillet, Cindy and Liu, Stephen V and Weinberg, Benjamin A and Cleary, James M and Calvo, Emiliano and Umemoto, Kumiko and Nagasaka, Misako and Springfeld, Christoph and Bekaii-Saab, Tanios and O'Kane, Grainne M and Opdam, Frans and Reiss, Kim A and Joe, Andrew K and Wasserman, Ernesto and Stalbovskaya, Viktoriya and Ford, Jim and Adeyemi, Shola and Jain, Lokesh and Jauhari, Shekeab and Drilon, Alexander and eNRGy Investigators, eNRGy Investigators},
  title = {Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {6},
  pages = {566--576},
  doi = {10.1056/nejmoa2405008}
}
Kostenlos starten →